Injectable microdepots for healthier joints & mobility
Learn more
liposome + peptide
CloudLi
CloudLi-1 combines an immunomodulatory peptide with our proprietary CloudLi™ technology, , designed for prolonged retention in the joint – targeting inflammation and cartilage degradation to address osteoarthritis progression and pain.
Today’s treatments leave too many patients behind.
Osteoarthritis is a leading cause of disability, which contributes to shorter health- and lifespan. Corticosteroid injections provide only short-term relief and are unsuitable for many patients. Hyaluronic acid has shown inconsistent benefit in clinical studies.
Platelet-rich plasma, while promising in some cases, is inherently variable because its quality depends on each individual patient. As a result, millions of people continue to live with pain and progressive joint degradation despite available options.
Local therapies struggle to maintain activity in the joint
Promising locally administered therapeutics can be rapidly cleared from the joint, limiting drug exposure and the duration of therapeutic activity where it is needed.
In osteoarthritis, persistent inflammation contributes to progressive cartilage degradation. Sustaining therapeutic activity within the joint could therefore be important for addressing both symptoms and disease progression.
CloudLi-1 is designed for prolonged local treatment of osteoarthritis
Our CloudLi™ technology is designed to prolong therapeutic retention within the joint.
An immunomodulatory peptide links liposomes into stable CloudLi clusters, enabling prolonged intra-articular retention and local anti-inflammatory activity — with the potential to reduce inflammation-driven cartilage degradation and OA progression.
Built on the versatile CloudLi™ platform, the technology combines prolonged local retention with selectable therapeutic linkers, creating opportunities for long-acting local therapies across osteoarthritis and other indications.
Our publications
Here’s some of Eldian Biomed’s work in osteoarthritis as the basis of CloudLi™. Earlier publications describe the first generation of our technology and the scientific foundation for today’s CloudLi™ platform, now being developed toward long-acting, disease-modifying therapeutics.
Our pipeline
CloudLi-1 is Eldian Biomed's osteoarthritis lead, built on the CloudLi™ platform, expandable to new indications. The platform is tuneable—linker choice enables features beyond anti-inflammation, such as tissue targeting—and it supports drug delivery.
Program | Disease | Discovery“In vivo” lead optimizationIND-enablingClinical |
|---|---|---|
| CloudLi-1 | Osteoarthritis | |
Funding our mission
Eldian Biomed is supported by highly competitive grants and fellowships, including Innosuisse, Gerbert Rüf Stiftung, Bridge PoC, Venture Kick, and the University of Bern Venture Fellowship. We are grateful to these institutions for their early belief in our vision.
Their support not only validates the disruptive potential of CloudLi™ but has been instrumental in transforming our scientific innovation into a tangible therapeutic path for osteoarthritis and beyond.
